Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
Gorby, Claire; Sotolongo Bellón, Junel; Wilmes, Stephan; Warda, Walid; Pohler, Elizabeth; Fyfe, Paul K.
Published in:
Science Signaling
DOI:
10.1126/scisignal.abc0653
Publication date:
2020

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):
https://doi.org/10.1126/scisignal.abc0653

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 19. Nov. 2023
a) Human buffy coat → PBMC isolation & activation → Anti-CD3/CD28 beads
   
   Untransduced
   
   +IL-2
   
   +IL-2 + WTD + R5A11D
   
   6 days
   
   IL-10 addition
   
   +IL-2
   
   Lenti Transduction
   
   +IL-2
   
   +IL-2 + WTD + R5A11D
   
   3 days
   
   Monomac Co-culture
   
   Live/Dead Cell Count

b) CD3
   
   IL-2
   
   IL-2+WTD
   
   IL-2+R5A11D
   
   Mock CAR T cells
   
   Anti-IL1RAP CAR T cells

Viable target cells (%)

Effector: Target Ratio

Mock CAR T Cells

Anti IL1RAP CAR T Cells